USE OF A 5-HT4 AGONIST FOR THE TREATMENT OF IRRITABLE BOWEL SYNDROME CHARACTERIZED BY MIXED OR ALTERNATING BOWEL HABITS

摘要

The invention relates to a pharmaceutical composition, use, or method in the treatment of Irritable Bowel Syndrome (IBS) characterized by mixed or alternating bowel habits based on a modification of the Rome II criteria (IBS-M), with 5-hydroxytryptamine type-4 receptor agonists (5-HT₄ agonists), in particular tegaserod.